Sort by
Appendix 4C and Quarterly Activities Report - September 2026
Notice of Annual General Meeting/Proxy Form
Proposed issue of securities - IVX
Funding Agreements Cover Up to 85% of Clinical Trials Costs
Photosoft and Novel Immunotherapy Collaboration Partnership
PER: Percheron and Invion Explore Cancer Combination Therapy
Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2
Application for quotation of securities - IVX
Proposed issue of securities - IVX
Director Loans
| Date | Headline |
|---|---|
29 Oct 2026 | Appendix 4C and Quarterly Activities Report - September 2026 |
23 Oct 2026 | Notice of Annual General Meeting/Proxy Form |
21 Oct 2026 | Proposed issue of securities - IVX |
21 Oct 2026 | Funding Agreements Cover Up to 85% of Clinical Trials Costs |
20 Oct 2026 | Photosoft and Novel Immunotherapy Collaboration Partnership |
20 Oct 2026 | PER: Percheron and Invion Explore Cancer Combination Therapy |
19 Oct 2026 | Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2 |
15 Oct 2026 | Application for quotation of securities - IVX |
29 Sep 2026 | Proposed issue of securities - IVX |
29 Sep 2026 | Director Loans |
